The role of tetracyclines in the treatment of non-specific urethritis

B. A. EVANS

From the Department of Genito-Urinary Medicine, West London Hospital, London

SUMMARY  An assessment of the clinical findings and treatment in 400 patients with non-specific urethritis (NSU) is reported, and the effect of treating their contacts is analysed. Three tetracyclines were compared in a randomised trial which showed that low-dose oxytetracycline (250 mg twice a day) was as effective as preparations formulated specifically for twice daily administration (triple tetracycline and sustained-release tetracycline hydrochloride). The question of multiple aetiology was explored by testing statistically whether various clinical features such as age, incubation period, severity of symptoms, and previous infection were related to outcome. No subgrouping of the condition could be found. Clinical relapse proved to be independent of empirical treatment of asymptomatic contacts, which therefore appeared not to confer any benefit on either partner. It is suggested that the infective aspect of NSU is readily controlled, and that other factors, probably psychological, determine relapse.

Introduction

Tetracyclines have consistently proved the most effective treatment for non-specific urethritis (King, 1973). Nevertheless, there is considerable disagreement with regard to daily dose, duration of treatment, and particular form of tetracycline most effective in curing the condition.

Another controversial aspect of the management of this condition is whether or not known contacts who show no clinical, bacteriological, or cytological abnormality should be treated empirically with a similar course of tetracycline.

This paper reports a randomised trial comparing three tetracyclines (oxytetracycline, triple tetracycline, and sustained-release tetracycline), each prescribed as one tablet twice daily for seven days. It also examines various factors, including treatment of contacts, which may be related to resolution of the condition.

Material and methods

The trial was undertaken on 400 patients seen in the Department of Genito-Urinary Medicine, West London Hospital, between April and September 1975. Patients who had been treated for NSU during the previous 12 months were excluded, as was anyone who had been given antibiotics during the past three months. Diagnosis of, or contact with, any other sexually transmissible disease also precluded acceptance for the trial, and so did any suggestion of tetracycline allergy.

Patients were allocated one of three treatments according to a prepared randomisation chart and the treatment given remained unknown to the prescriber until after the outcome had been assessed. These regimens were oxytetracycline, 250 mg twice daily, triple tetracycline (Deteclo) 1 tablet twice daily, and sustained-release tetracycline (Sustamycin) 1250 mg capsule twice daily, each continued for seven days. Attendance for assessment was requested at one week, two weeks, and four weeks after the start of treatment.

Smears of urethral exudate were examined using a ×100 oil immersion objective lens and the diagnosis was based on the presence of more than 10 polymorphonuclear leucocytes (PMN) in five microscope fields. Additional investigations consisted of culture for Neisseria gonorrhoeae and macroscopical examination of the urine for urethral threads. Patients were regarded as cured if their urethral smear was normal and they had held their urine for more than two hours. The urine was routinely examined for threads at each follow-up attendance and a clear
urethral flush of urine provided equally good evidence of resolution. No patient was assessed for
the trial until three months from starting treatment, thus ensuring that late relapses were not omitted
from the results. The statistical significance of the results was assessed using the χ² test.

All patients were asked to invite their recent sexual contacts to attend for examination, and a contact
slip was provided to verify the reason for their attendance.

Results

The ages of the 400 patients admitted to the trial ranged between 16 and 59 years (mean 28 years); 22
(5.5%) were homosexual. Forty-eight patients (12%) had to be taken out of the trial for a wide
variety of reasons; of these 29 required treatment for other conditions, including gonorrhoea (three cases),
trichomoniasis (two cases) and contact with trichomoniasis (five cases), genital warts (eight cases),
and treponemal infection (five cases, two of which were early syphilis), and in most of the remainder
the criteria of the protocol had not been fulfilled. Altogether 133 patients (33%) defaulted before two
weeks’ observation had been completed, leaving 219 patients who could be adequately assessed regarding
the outcome of their treatment. These results are summarised in Table 1.

Table 1 Outcome of trial

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Drug group</th>
<th>Total patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oxytetracycline</td>
<td>Triple tetracycline</td>
</tr>
<tr>
<td>Removed</td>
<td>18</td>
<td>11</td>
</tr>
<tr>
<td>Defaulted</td>
<td>47</td>
<td>41</td>
</tr>
<tr>
<td>Relapsed</td>
<td>22</td>
<td>29</td>
</tr>
<tr>
<td>Cured</td>
<td>47</td>
<td>51</td>
</tr>
<tr>
<td>Total</td>
<td>134</td>
<td>132</td>
</tr>
</tbody>
</table>

There was no significant difference between the results of treatment with the three tetracyclines no
matter which procedure was used to evaluate the outcome (p = 0.7). In fact, low dose oxytetracycline
produced marginally the best results: only 22 (19%) of those patients who received this drug required
further treatment during the next three months, compared with 25 patients (22%) of those who
received sustained-release tetracycline and 29 (24%) of those who received triple tetracycline. There was
also no difference between the results with the three tetracyclines in respect of whether the relapse was
early (two to four weeks from treatment) or late (one to three months from treatment). This is shown
in Table 2.

Table 2 Relapse of NSU

<table>
<thead>
<tr>
<th>Relapse</th>
<th>Drug group</th>
<th>Total patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oxytetracycline</td>
<td>Triple tetracycline</td>
</tr>
<tr>
<td>Early (2-4 weeks)</td>
<td>16</td>
<td>22</td>
</tr>
<tr>
<td>Late (1-3 months)</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>29</td>
</tr>
</tbody>
</table>

Patients who had had a contact treated were grouped according to the outcome of their own
response to treatment (Table 3). This shows no significant difference between the relapse and no
relapse groups (p = 0.6). However, there was a marked difference in admitted re-exposure between
those patients relapsing within a month of treatment (14.5%) and those who relapsed later (90%); subse-
quently the sexual intercourse was not recorded in the relapse-free group.

Table 3 Treatment of contacts of patients with NSU

<table>
<thead>
<tr>
<th>Patients with NSU</th>
<th>Relapse</th>
<th>No relapse</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early</td>
<td>Late</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>55</td>
<td>21</td>
<td>143</td>
</tr>
<tr>
<td>No. with treated contact</td>
<td>17 (30%)</td>
<td>6 (29%)</td>
<td>33 (23%)</td>
</tr>
<tr>
<td>Delay before treatment (days)</td>
<td>4-0</td>
<td>7-1</td>
<td>4-6</td>
</tr>
<tr>
<td>Range</td>
<td>0-12</td>
<td>0-28</td>
<td>0-24</td>
</tr>
<tr>
<td>History of re-exposure</td>
<td>8 (15%)</td>
<td>19 (90%)</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Other factors which might have influenced the outcome of treatment are recorded in Table 4. No significant
difference emerged in respect of age, duration of symptoms, interval since sexual intercourse, or microscopical assessment of urethral discharge between the three treatment groups. A
history of NSU did not appear more commonly in

Table 4 Other clinical findings with possible influence on outcome

<table>
<thead>
<tr>
<th>Clinical findings</th>
<th>Relapse</th>
<th>No relapse</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean years)</td>
<td>27-7</td>
<td>27-7</td>
<td>27-6</td>
</tr>
<tr>
<td>Duration of symptoms</td>
<td>7.5</td>
<td>14-2</td>
<td>9-5</td>
</tr>
<tr>
<td>Interval since sexual intercourse (mean days)</td>
<td>11-1</td>
<td>15-0</td>
<td>12-7</td>
</tr>
<tr>
<td>Microscopical pus in discharge (mean +/−*)</td>
<td>2-2</td>
<td>1-8</td>
<td>1-7</td>
</tr>
<tr>
<td>Previous NSU (total patients)</td>
<td>20</td>
<td>6</td>
<td>34</td>
</tr>
</tbody>
</table>

* + + +0-20 PMN/HPF; + + + +0-40 PMN/HPF; ++ ++ + +0-40 PMN/HPF.
the relapsing patients \( (p = 0.3) \), although no patient who had had NSU during the previous year had been admitted to the trial.

It had been planned that a urethral smear at four weeks should be the test of cure, but in practice only about a quarter of patients actually had this test (Table 5). This deficiency renders the quotation of a cure rate unacceptable, particularly as five patients who were found to have relapsed were asymptomatic. Therefore the figures have been given for re-treatment during a three-month period, a concept used by Willcox et al. (1975), which permits comparison with a large bibliography of previous trials.

Table 5 Tests of cure

<table>
<thead>
<tr>
<th>Test of cure</th>
<th>Drug group</th>
<th>Total patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline</td>
<td>Triple tetracycline</td>
<td>Sustained-release tetracycline</td>
</tr>
<tr>
<td>Urethral smear</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Urethral flush only</td>
<td>19</td>
<td>22</td>
</tr>
<tr>
<td>Total</td>
<td>51</td>
<td>54</td>
</tr>
</tbody>
</table>

The Figure shows the diagnosis of relapse against time from treatment and illustrates that this continues right to the end of the arbitrary three-month period, which ought therefore to be extended.

![Figure](http://sti.bmj.com/)

**Figure** Interval between initial treatment of NSU and diagnosis of relapse.

**Discussion**

Treatment of NSU with a single course of a tetracycline was unsuccessful in 10 to 20% of patients observed during a period of three months (Willcox et al., 1975). Prolonged courses lasting up to three weeks have been advocated, but the results reported fall within the figures quoted above (John, 1971; Bhattacharyya and Morton, 1973). The current trial is the first to report the effect of low-dose oxytetracycline (250 mg twice daily). That these results should be comparable with standard and even prolonged chemotherapy, suggests that NSU is a mild infection easily cured, a view supported by a placebo cure rate of 34% (Fowler, 1970). Why then is there so commonly a relapse in 10 to 20% of cases, independent of the amount of tetracyclines given?

Treatment of contacts on an empirical basis is widely accepted as necessary, but this has not been validated statistically, and no evidence has appeared to support treatment of contacts (Rosedale, 1959). Figures from this trial show that only 26% of patients had a contact treated, and that this did not relate significantly to the patients who relapsed or to those who did not \( (p = 0.6) \). Clinical findings are strikingly normal in contacts of NSU, and the incidence of trichomoniasis and candidosis is lower than in a clinic population overall (unpublished observations). Perhaps the cause of NSU is spontaneously eliminated from the female genital tract. Another possibility is that some men acquire immunity during the course of clinical infection, or perhaps develop tolerance to the organism subclinically.

There also appears to be no way of distinguishing separate clinical groups of patients in relation to their treatment responses. Neither the duration of symptoms nor the purulence of the discharge, which provide indices of the severity of the urethritis, was related to outcome. The interval since sexual intercourse was used as a parameter for incubation, but this also failed to identify possible subgroups of NSU.

The finding of a past history might suggest predisposition to NSU. Cases treated within the previous year were excluded in order to minimise biased response from those who may then have received oxytetracycline in larger dosage. Nevertheless, patients with a more distant history of NSU were proportionately distributed between the relapse and no relapse groups.

Additional evidence against re-infection lies in the denial of further intercourse by 85% of patients relapsing in the first month. This finding, taken in conjunction with the recent report that *Chlamydia trachomatis* was not isolated from any patient with relapsed NSU within six weeks of initial treatment (Handsfield et al., 1976), provides another indication that relapse may not be infective. In complete contrast, re-exposure was admitted by 90% of those who relapsed later. Unfortunately, this question was not asked of cured patients, whose behaviour might have been similar.
The role of tetracyclines in the treatment of non-specific urethritis

It is possible that psychological factors may play a major part in determining relapse; erratic or incomplete compliance with intermittent medication is well known. Excessive and repeated physical examination of the urethra, particularly by the patient, may well maintain a continuous discharge as a result of persistent mucosal irritation, and psychosomatic elements may also come into play. This hypothesis is difficult to test, but a long-term prospective study in this Department using psychometric tests is currently looking at various personality factors, including hypochondriasis, in this connection.

The author wishes to thank Mr James Bennett, SRN, RMN and his colleagues for invaluable help in the conduct of the trial.

References


The role of tetracyclines in the treatment of non-specific urethritis.
B A Evans

*Br J Vener Dis* 1977 53: 40-43
doi: 10.1136/sti.53.1.40

Updated information and services can be found at:
http://sti.bmj.com/content/53/1/40

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/